As part of its mission the CIP takes the lead in planning and recruiting for a number of imaging-related clinical trials, as summarized on the Web site at: http://imaging. cancer.gov/ clinicaltiials/. These include screening and interventional trials, trials assessing imaging response criteria, single-institution feasibility trials (R21), phase 1 and 2 trials, and ACRIN trials. Current phase 3 ACRIN trials all involve PET, including PET to: monitor treatment for malignant gastrointestinal stromal tumors, predict treatment response in lung cancer, and evaluate treatment response in lung cancer.